



*Chandra Bhagat Pharma Limited*

To,

Date: 13/11/2021

**The Manager,  
Corporate Compliance Department  
BSE Limited  
Phiroze Jeejeebhoy Tower,  
Dalal Street,  
Mumbai-400001.  
Scrip Code: (BSE-542934)**

**Sub:-Outcome of Board Meeting held on Saturday, 13<sup>th</sup> November, 2021 pursuant to the Regulation 30 of Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulation 2015(“Listing Regulation”).**

Dear Sir/Madam,

The Board of Directors of the Company in their meeting held on 13<sup>th</sup> November, 2020 at Registered Office of Company viz. 323-F, Bhagat Bhuvan, Dr. Ambedkar Road, Matunga East, Mumbai-400019, which commenced at 05:30 pm and concluded at 06:30 pm inter alia, approved the Un-Audited Financial Result of the Company for the half year ended on 30<sup>th</sup> September, 2021 along with the Limited Review Report thereon furnished by the Statutory Auditor of the Company in compliance with Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015.

In accordance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulation, 2015 and Company’s code of conduct for prohibition of Insider Trading, The “Trading Window” for trading in the shares of the Company will open after 48 hours from Announcement of Financial Statement for the Directors and Key Managerial Personnel/Designated Employees/ Connected person of the Company as defined in the code of conduct for prohibition of Insider Trading of the Company.



## Chandra Bhagat Pharma Limited

Kindly take the above on record and inform all those concerned accordingly.

Yours Sincerely,

**FOR CHANDRA BHAGAT PHARMA LIMITED**

A handwritten signature in black ink, appearing to read 'Hemant C Bhagat', is written over a thin, light-colored horizontal line.

**HEMANT C BHAGAT**

**Director**

**DIN: 00233530**

**Limited Review Report on the half yearly Unaudited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, As Amended****Review Report****To****The Board of Directors  
Chandra Bhagat Pharma Limited**

1. We have reviewed the accompanying statement of unaudited financial results of **Chandra Bhagat Pharma Limited** (the 'Company') for the Half Year ended on September 30, 2021 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('the Regulation') as amended, read with SEBI Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 and Circular No. CIR/CFD/CMD1/80/2019 dated July 19, 2019 ('the Circular').
2. The preparation of the Statement in accordance with the recognition and measurement principles laid down in Accounting Standard 25, "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, read with the Circular is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited financial results, prepared in accordance with applicable Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with circular no. CIR/CFD/FAC/62/2016 dated July 05, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For A Y & Company  
Chartered Accountants  
FRN: 020829C**  
**Arpit Gupta  
Partner****M. No. 421544****UDIN – 21421544AAAADH7525****Place: Mumbai****Date: 13.11.2020**



# CHANDRA BHAGAT PHARMA LIMITED

CIN No: U24230MH2003PLC139534

323-F BHAGAT BHUVAN DR.AMBEDKAR ROAD MATUNGA (EAST) - MUMBAI MAHARASHTRA- 400019 Email : compliancecbe@gmail.com

Statement of Unaudited Financial Results for the half year ended on September 30, 2021 Pursuant to regulation 33 of SEBI (LODR) Regulation, 2015

| Particulars  | Six Months Ended on 30/09/2021<br>(Amount in Rs.) | Six Months Ended on 31/03/2021<br>(Amount in Rs.) | Six Months Ended on 30/09/2020<br>(Amount in Rs.) | Year to Date as on 30/09/2021<br>(Amount in Rs.) | Year to date figures for year ended 31/03/2021 (Amount in Rs.) |
|--|---|---|---|--|--|
|  | Unaudited   | Audited   | Unaudited   | Unaudited  | Audited  |
| <b>INCOME FROM OPERATIONS</b>                                      |   |   |   |  |  |
| I Revenue from Operations  | 431,492,316                                       | 483,309,080                                       | 223,644,110                                       | 431,492,316                                      | 706,953,190  |
| II Other Income  | 4,685,241   | 4,582,926   | 174,621   | 4,685,241  | 4,757,547  |
| III <b>Total Income from Operations</b>                            | <b>436,177,557</b>                                | <b>487,892,006</b>                                | <b>223,818,731</b>                                | <b>436,177,557</b>                               | <b>711,710,737</b>   |
| <b>IV EXPENSES</b>   |   |   |   |  |  |
| Cost of Material Consumed  | 25,194,040  | 91,335,398  | -   | 25,194,040                                       | 91,335,398   |
| Purchase of Stock in Trade   | 346,564,518                                       | 248,029,068                                       | 198,458,263                                       | 346,564,518                                      | 446,487,331  |
| Change in inventories of Finished Goods, WIP & Stock in Trade      | (15,541,378)                                      | 72,121,840  | (12,540,662)                                      | (15,541,378)                                     | 59,581,178   |
| Employee benefit expenses  | 7,116,979   | 14,454,339  | 5,930,786   | 7,116,979  | 20,385,125   |
| Finance Cost   | 14,511,898  | 18,617,947  | 16,217,692  | 14,511,898                                       | 34,835,639   |
| Depreciation & Amortization Expense                                | 590,670   | 230,563   | 104,126   | 590,670  | 334,689  |
| Other Expenses   | 51,968,531  | 40,727,999  | 15,234,630  | 51,968,531                                       | 55,962,629   |
| <b>Total expenses (IV)</b>   | <b>430,405,258</b>                                | <b>485,517,154</b>                                | <b>223,404,835</b>                                | <b>430,405,258</b>                               | <b>708,921,989</b>   |
| V <b>Profit/(loss) before Exceptional Items &amp; Tax (III-IV)</b> | <b>5,772,300</b>                                  | <b>2,374,852</b>                                  | <b>413,896</b>                                    | <b>5,772,300</b>                                 | <b>2,788,748</b>   |
| VI Exceptional Items   | -   | -   | -   | -  | -  |
| VII <b>Profit/(loss) before tax (VIII-IX)</b>                      | <b>5,772,300</b>                                  | <b>2,374,852</b>                                  | <b>413,896</b>                                    | <b>5,772,300</b>                                 | <b>2,788,748</b>   |
| X <b>Tax Expenses</b>  |   |   |   |  |  |
| 1 Current Tax  | 1,420,676   | 689,675   | 105,639   | 1,420,676  | 795,314  |
| 2 Deferred Tax   | 29,123  | 131,392   | (36,759)  | 29,123   | 94,633   |
| <b>Total Tax Expenses (XI)</b>                                     | <b>1,449,800</b>                                  | <b>821,067</b>                                    | <b>68,880</b>                                     | <b>1,449,800</b>                                 | <b>889,947</b>   |
| XI <b>Profit/(Loss) after Tax (X-XI)</b>                           | <b>4,322,500</b>                                  | <b>1,553,785</b>                                  | <b>345,016</b>                                    | <b>4,322,500</b>                                 | <b>1,898,801</b>   |
| XII <b>Paid up Equity Share Capital</b>                            | <b>75,450,560</b>                                 | <b>75,450,560</b>                                 | <b>75,450,560</b>                                 | <b>75,450,560</b>                                | <b>75,450,560</b>  |
| XIII <b>Reserves &amp; Surplus</b>                                 | <b>187,660,015</b>                                | <b>183,337,515</b>                                | <b>181,783,730</b>                                | <b>187,660,015</b>                               | <b>183,337,515</b>   |
| XIV <b>Earnings per equity share</b>                               |   |   |   |  |  |
| (1) Basic  | 0.57  | 0.21  | 0.05  | 0.57   | 0.25   |
| (2) Diluted  | 0.57  | 0.21  | 0.05  | 0.57   | 0.25   |

For Chandra Bhagat Pharma Limited

Hemant C Bhagat  
Chairman Cum Managing Director  
DIN : 00233530

Place : Mumbai  
Date : November 13, 2021





# CHANDRA BHAGAT PHARMA LIMITED

CIN No: U24230MH2003PLC139534

323-F BHAGAT BHUVAN DR.AMBEDKAR ROAD MATUNGA (EAST) - MUMBAI MAHARASHTRA- 400019 Email :  
compliancecbc@gmail.com


Statement of Assets & Liabilities as at September 30, 2021

| Particulars   | As at September 30, 2021<br>(Amount in Rs.) | As at March 31, 2021<br>(Amount in Rs.) |
|---|---|---|
|   | Unaudited                                   | Unaudited                               |
| <b>I. Equity and Liabilities</b>                                  |   |   |
| <b>Shareholders Fund</b>  |   |   |
| Share Capital   | 75,450,560                                  | 75,450,560                              |
| Reserves & Surplus  | 187,660,015                                 | 183,337,515                             |
|   | <b>263,110,575</b>                          | <b>258,788,075</b>                      |
| <b>Non-current liabilities</b>                                    |   |   |
| Long Term Borrowings  | 92,713,367                                  | 94,511,556                              |
| Deferred tax liabilities (Net)                                    | 125,877                                     | 96,754                                  |
| Other Long Term Liabilities                                       | 35,223,190                                  | 35,705,526                              |
|   | <b>128,062,434</b>                          | <b>130,313,836</b>                      |
| <b>Current liabilities</b>  |   |   |
| Short Term Borrowings   | 160,780,254                                 | 156,339,235                             |
| Trade payables  |   |   |
| (a) total outstanding dues of micro and small enterprises         |   |   |
| (b) total outstanding dues other than micro and small enterprises | 155,338,505                                 | 128,536,518                             |
| Other current liabilities   | 23,272,167                                  | 43,039,950                              |
| Short term Provisions   | 1,420,676                                   | 795,314                                 |
|   | <b>340,811,602</b>                          | <b>328,711,017</b>                      |
| <b>Total</b>  | <b>731,984,612</b>                          | <b>717,812,928</b>                      |
| <b>II.Assets</b>  |   |   |
| <b>Non-current assets</b>   |   |   |
| Fixed assets  |   |   |
| Tangible Assets   | 4,298,807                                   | 4,227,040                               |
| Capital WIP   | -   | -                                       |
| Intangible Assets   | -   | -                                       |
| Other Non Current Assets  | 13,058,124                                  | 13,486,349                              |
| Deferred Tax Assets (Net)   | -   | -                                       |
|   | <b>17,356,931</b>                           | <b>17,713,389</b>                       |
| <b>Current Assets</b>   |   |   |
| Investments   | 1,187,148                                   | 4,003,469                               |
| Inventories   | 356,831,651                                 | 351,391,739                             |
| Trade Receivables   | 94,580,572                                  | 154,181,542                             |
| Cash & Bank Balances  | 32,001,764                                  | 24,208,229                              |
| Short Term loans & advances                                       | 225,328,419                                 | 163,407,247                             |
| Other current Assets  | 4,698,127                                   | 2,907,313                               |
|   | <b>714,627,681</b>                          | <b>700,099,539</b>                      |
| <b>Total</b>  | <b>731,984,612</b>                          | <b>717,812,928</b>                      |

**Notes:-**

1. The above Unaudited Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meeting held on November 13, 2021
2. The Statutory Auditors of the Company have carried out the Limited Review of these Results
3. There are no investor complaints received/pending as on September 30, 2021
4. Previous year's/ period figures have been regrouped/ reclassified/ restated, wherever necessary to confirm to classification of current year/period.

For Chandra Bhagat Pharma Limited

  
Hemant C Bhagat  
Chairman Cum Managing Director  
DIN : 00233530



Place : Mumbai  
Date : November 13, 2021



# Chandra Bhagat Pharma Limited

(Formerly Known as Chandra Bhagat Pharma Private Limited)

CIN No: U24230MH2003PLC139534

Cash Flow Statement for the period ended September 30, 2021

| Cash flow statement as at   | 30 September 2021<br>(Amount in Rs.) | 30 September 2020<br>(Amount in Rs.) |
|---|--------------------------------------|--------------------------------------|
| <b>Cash flow from operating activities</b>                                  |                                      |                                      |
| Net Profit before tax and extraordinary items                               | 5,772,300                            | 413,896                              |
| <b>Non-Cash adjustment to reconcile profit before tax to net cash flows</b> |                                      |                                      |
| Depreciation  | 162,445                              | 104,126                              |
| Interest Received   | (2,143)                              | (127,905)                            |
| Finance Cost  | 14,511,898                           | 16,217,692                           |
| <b>Operating profit before Working Capital changes</b>                      | <b>20,444,500</b>                    | <b>16,607,809</b>                    |
| <b>Change in Working Capital</b>  | <b>299,597</b>                       | <b>26,641,439</b>                    |
| Increase/(Decrease) in Trade Payables                                       | 26,801,987                           | (4,978,806)                          |
| Increase/(Decrease) in Other current Liabilities                            | (19,767,783)                         | 6,344,219                            |
| Decrease/(Increase) in Inventories  | (5,439,912)                          | (12,540,664)                         |
| Decrease/(Increase) in Trade receivables                                    | 59,600,970                           | 17,295,245                           |
| Decrease/(Increase) in Short term Loans and advances                        | (61,921,172)                         | 16,761,535                           |
| Decrease/(Increase) in Other Current Assets                                 | (1,790,814)                          | 3,875,025                            |
| Decrease/(Increase) in Investments  | 2,816,321                            | (115,115)                            |
| <b>Cash generated from operations</b>                                       | <b>20,744,097</b>                    | <b>43,249,248</b>                    |
| Income Tax(Paid)/ Refund  | 795,314                              | -                                    |
| <b>Net Cash flow from / (used in) Operating activities (A)</b>              | <b>19,948,783</b>                    | <b>43,249,248</b>                    |
| <b>Cash Flow from/(used in) Investing Activities</b>                        |                                      |                                      |
| Purchase of Fixed Assets  | (234,212)                            | (139,969)                            |
| Interest received   | 2,143                                | 127,905                              |
| (Increase)/Decrease in Other Non Current Assets                             | 428,225                              | 436,081                              |
| <b>Net Cash (used in) Investing activities (B)</b>                          | <b>196,156</b>                       | <b>424,017</b>                       |
| <b>Cash Flow from/ (used in) Financing Activities</b>                       |                                      |                                      |
| Finance Cost  | (14,511,898)                         | (16,217,692)                         |
| Proceeds/ (Repayment) of Short term Borrowings                              | 4,441,019                            | 2,383,164                            |
| Proceeds/ (Repayment) of Long term Borrowings                               | (1,798,189)                          | (14,960,029)                         |
| Proceeds/ (Repayment) of Other long Term Liabilities                        | (482,336)                            | (6,400)                              |
| <b>Net Cash flow from / (used in) financing activities (C)</b>              | <b>(12,351,404)</b>                  | <b>(28,800,957)</b>                  |
| <b>Net Increase / (Decrease) in Cash and Cash Equivalents (A+B+C)</b>       | <b>7,793,535</b>                     | <b>14,872,308</b>                    |
| Cash and Cash Equivalents at the beginning of the year                      | 24,208,229                           | 4,779,839                            |
| <b>Cash and Cash Equivalents at the end of the year</b>                     | <b>32,001,764</b>                    | <b>19,652,147</b>                    |

For Chandra Bhagat Pharma Limited

Hemant C Bhagat  
Chairman Cum Managing Director  
DIN : 00233530



Place : Mumbai  
Date : November 13, 2021